Non Tuberculos mycobacterium ( mycobactriods abcess)

Reading File
Finding Sources
Finding Sources
Searching PubMed

Mycobacterium abscessus treatment outcomes

Reading File
Reading File
Reading File
Reading File
Finding Sources
Searching Images

Mycobacterium abscessus nontuberculous mycobacteria NTM lung infection chest CT

This Comparison Chart displays ten axial chest CT scan slices from a patient with a pulmonary Mycobacterium abscessus infection, illustrating disease progression and treatment response. Panels A-E (top row) represent pre-treatment baseline imaging, while panels F-J (bottom row) show the same anatomical levels following the initial phase of medical therapy. The pre-treatment scans (A-E) demonstrate multiple active pathologies: large thick-walled pulmonary cavities in the right lung (indicated by red arrows in panels C and D) and extensive bilateral 'tree-in-bud' opacities (indicated by blue arrows), which represent centrilobular nodules and branching linear structures characteristic of small-airway impaction and endobronchial spread of infection. In the post-treatment scans (F-J), there is a visible radiological improvement characterized by a significant reduction in the size and wall thickness of the cavities (red arrows in H and I) and a marked decrease in the density and distribution of the tree-in-bud lesions (blue arrows). The image serves as a clinical illustration of antibiotic efficacy in treating nontuberculous mycobacteria (NTM) lung disease, specifically highlighting the resolution of bronchogenic spread and cavitary lesions.

This Comparison Chart displays ten axial chest CT scan slices from a patient with a pulmonary Mycobacterium abscessus infection, illustrating disease progression and treatment response. Panels A-E (top row) represent pre-treatment baseline imaging, while panels F-J (bottom row) show the same anatomical levels following the initial phase of medical therapy. The pre-treatment scans (A-E) demonstrate multiple active pathologies: large thick-walled pulmonary cavities in the right lung (indicated by red arrows in panels C and D) and extensive bilateral 'tree-in-bud' opacities (indicated by blue arrows), which represent centrilobular nodules and branching linear structures characteristic of small-airway impaction and endobronchial spread of infection. In the post-treatment scans (F-J), there is a visible radiological improvement characterized by a significant reduction in the size and wall thickness of the cavities (red arrows in H and I) and a marked decrease in the density and distribution of the tree-in-bud lesions (blue arrows). The image serves as a clinical illustration of antibiotic efficacy in treating nontuberculous mycobacteria (NTM) lung disease, specifically highlighting the resolution of bronchogenic spread and cavitary lesions.

This figure presents two transverse chest computed tomography (CT) scans (axial view) illustrating the progression and treatment response of nontuberculous mycobacterial (NTM) lung disease. Scan (a) shows the initial presentation, characterized by bilateral bronchiectasis and pulmonary consolidations, specifically prominent in the right middle lobe and the lingular division of the left upper lobe (white arrows). Multiple 'tree-in-bud' opacities (black arrow) are visible in the peripheral lung zones, signifying active bronchiolitis and infectious small airway involvement. Scan (b) displays the same anatomical level after 12 months of antibiotic therapy, demonstrating a clear interval reduction in the density and extent of the consolidations (white arrows) and a significant decrease in the tree-in-bud appearances (black arrow). The images illustrate the classic radiographic features of the nodular bronchiectatic form of Mycobacterium abscessus infection and its typical response to targeted pharmacological intervention.

This figure presents two transverse chest computed tomography (CT) scans (axial view) illustrating the progression and treatment response of nontuberculous mycobacterial (NTM) lung disease. Scan (a) shows the initial presentation, characterized by bilateral bronchiectasis and pulmonary consolidations, specifically prominent in the right middle lobe and the lingular division of the left upper lobe (white arrows). Multiple 'tree-in-bud' opacities (black arrow) are visible in the peripheral lung zones, signifying active bronchiolitis and infectious small airway involvement. Scan (b) displays the same anatomical level after 12 months of antibiotic therapy, demonstrating a clear interval reduction in the density and extent of the consolidations (white arrows) and a significant decrease in the tree-in-bud appearances (black arrow). The images illustrate the classic radiographic features of the nodular bronchiectatic form of Mycobacterium abscessus infection and its typical response to targeted pharmacological intervention.

Diagnostic Image: This figure presents multiple axial high-resolution computed tomography (CT) scans of the chest from two different clinical cases of non-tuberculous mycobacteria lung disease (NTM-LD). 

Panel A (Top): Displays axial slices of an immunocompromised patient with Mycobacterium asiaticum infection. Notable findings include severe, extensive varicose bronchiectasis characterized by significant bronchial dilation and bronchial wall (parietal) thickening, highlighted by black arrows. Also visible are areas of centrilobular opacities with ground-glass attenuation, indicating small-airway involvement.

Panel B (Bottom): Shows axial slices from a patient with Mycobacterium avium-intracellulare (MAC) complex. The left slice demonstrates focal consolidation and associated bronchiectasis localized to the right middle lobe. The right slice highlights ground-glass centrilobular opacities in the lingula and lower lobes (black arrows). 

Educational Significance: These images demonstrate typical radiological patterns of NTM-LD, including the 'nodular bronchiectatic' form which often involves the middle lobe and lingula, and the more severe cavitary/varicose form seen in immunocompromised states.

Diagnostic Image: This figure presents multiple axial high-resolution computed tomography (CT) scans of the chest from two different clinical cases of non-tuberculous mycobacteria lung disease (NTM-LD). Panel A (Top): Displays axial slices of an immunocompromised patient with Mycobacterium asiaticum infection. Notable findings include severe, extensive varicose bronchiectasis characterized by significant bronchial dilation and bronchial wall (parietal) thickening, highlighted by black arrows. Also visible are areas of centrilobular opacities with ground-glass attenuation, indicating small-airway involvement. Panel B (Bottom): Shows axial slices from a patient with Mycobacterium avium-intracellulare (MAC) complex. The left slice demonstrates focal consolidation and associated bronchiectasis localized to the right middle lobe. The right slice highlights ground-glass centrilobular opacities in the lingula and lower lobes (black arrows). Educational Significance: These images demonstrate typical radiological patterns of NTM-LD, including the 'nodular bronchiectatic' form which often involves the middle lobe and lingula, and the more severe cavitary/varicose form seen in immunocompromised states.

This diagnostic image consists of a 24-panel mosaic (labeled A–X) of axial chest CT scans demonstrating various pulmonary manifestations of Non-Tuberculous Mycobacteria (NTM) infections. The collection illustrates a spectrum of pathological patterns including small pulmonary nodules (prominent in A, B, S, T), patchy ground-glass opacities (E, F, M, W), and dense lobar or segmental consolidation (C, D). Some sections (G, H) show evidence of reduced lung volume and structural distortion, while others (I, J, K, L, R, V) demonstrate post-treatment intervals with relative clearing of parenchymal disease and more distinct bronchovascular markings. The images provide a comparison of disease morphology across different NTM species, such as Mycobacterium avium complex and M. abscessus. Educational focus is placed on recognizing the radiologic hallmarks of chronic mycobacterial lung disease, monitoring treatment response, and identifying the heterogeneity of infectious presentations in different patients.

This diagnostic image consists of a 24-panel mosaic (labeled A–X) of axial chest CT scans demonstrating various pulmonary manifestations of Non-Tuberculous Mycobacteria (NTM) infections. The collection illustrates a spectrum of pathological patterns including small pulmonary nodules (prominent in A, B, S, T), patchy ground-glass opacities (E, F, M, W), and dense lobar or segmental consolidation (C, D). Some sections (G, H) show evidence of reduced lung volume and structural distortion, while others (I, J, K, L, R, V) demonstrate post-treatment intervals with relative clearing of parenchymal disease and more distinct bronchovascular markings. The images provide a comparison of disease morphology across different NTM species, such as Mycobacterium avium complex and M. abscessus. Educational focus is placed on recognizing the radiologic hallmarks of chronic mycobacterial lung disease, monitoring treatment response, and identifying the heterogeneity of infectious presentations in different patients.

Finding Sources
Finding Sources
Reading File
Reading File
Reading File
I now have comprehensive information. Let me compile the full answer.

Nontuberculous Mycobacteria (NTM) - Focus on Mycobacterium abscessus


Overview of NTM

More than 180 species of NTM have been identified. They are environmental organisms found ubiquitously in soil, water, and food. They cause disease primarily in persons with:
  • Pre-existing pulmonary disease (bronchiectasis, COPD, cystic fibrosis)
  • Immunocompromise (HIV/AIDS, organ transplant, biologics)
  • Nodular/bronchiectatic disease in otherwise healthy hosts (classic Lady Windermere syndrome - non-smoking white women >60 years old)
NTM are not transmitted person-to-person (except rare exceptions like M. abscessus in CF patients via indirect contact).
(Harrison's Principles of Internal Medicine 22E, 2025)

Classification: Runyon System

GroupGrowth RateExamples
I - PhotochromogensSlowM. kansasii, M. marinum
II - ScotochromogensSlowM. gordonae, M. scrofulaceum
III - NonchromogensSlowM. avium complex (MAC), M. xenopi
IV - Rapid GrowersFast (<7 days)M. abscessus, M. fortuitum, M. chelonae
M. abscessus belongs to Runyon Group IV - rapidly growing mycobacteria (RGM).
(Goodman & Gilman's Pharmacological Basis of Therapeutics)

Mycobacterium abscessus - Key Facts

Subspecies

  • M. abscessus subsp. abscessus - harbors erm(41) gene → inducible macrolide resistance
  • M. abscessus subsp. massiliense - truncated/nonfunctional erm(41) → macrolide susceptible, better treatment outcomes
  • M. abscessus subsp. *bolletii

Epidemiology

  • 3rd most common NTM pathogen in the United States
  • Endemic in southeastern states (Texas to Florida)
  • Environmental reservoir: tap water is the major source
  • Healthcare outbreaks linked to: dental unit water lines, polyethylene ear tubes, contaminated surgical equipment, cosmetic procedures (tattooing, acupuncture, pedicures)

Clinical Presentations

SiteDetails
PulmonaryMost common; often in nonsmoking white women >60 without underlying lung disease, OR in cystic fibrosis patients
Skin/Soft Tissue/BoneAfter accidental trauma, surgery, cosmetic procedures, tattoos, injections
LymphadenitisLess common than MAC
Catheter-associatedIV line infections, especially post-surgery
Otitis mediaAssociated with polyethylene ear tubes
DisseminatedImmunocompromised hosts (HIV, transplant)
(Red Book 2021; Washington Manual of Medical Therapeutics)

Diagnosis

ATS/IDSA Criteria for NTM Pulmonary Disease:
  • Significant clinical manifestations AND/OR radiographic evidence of progressive disease, PLUS:
    • Reproducible positive sputum cultures (≥2 positive cultures), OR
    • A single positive bronchoscopy culture
Radiology findings on chest CT:
  • Tree-in-bud opacities
  • Bronchiectasis (often middle lobe / lingula - "Lady Windermere" pattern)
  • Cavitary lesions (in fibrocavitary form)
  • Nodular infiltrates
NTM pulmonary disease - M. abscessus chest CT showing cavitary lesions (red arrows) and tree-in-bud opacities (blue arrows), with pre- and post-treatment comparison
Nodular bronchiectatic form of M. abscessus - bilateral bronchiectasis and consolidations with tree-in-bud opacities, showing 12-month treatment response
Microbiology:
  • RGM grow on culture media in < 7 days (subcultures)
  • AFB smear positive (weakly acid-fast)
  • Definitive ID by: PCR, 16S rRNA gene sequencing, MALDI-TOF
  • Susceptibility testing is mandatory - routine anti-TB drugs are ineffective

Antimicrobial Susceptibility

M. abscessus is resistant to most standard anti-TB agents. Potentially active drugs include:
  • Macrolides (clarithromycin, azithromycin) - BUT see resistance caveat below
  • Amikacin
  • Imipenem / cefoxitin
  • Tigecycline
  • Linezolid
  • Clofazimine
  • Trimethoprim-sulfamethoxazole
  • Ciprofloxacin (variable)

Critical Resistance Mechanism: erm(41) Gene

M. abscessus subsp. abscessus harbors an inducible macrolide resistance gene (erm41) - this methylates the ribosomal binding site and becomes apparent only after 3-5 days of macrolide incubation. Isolates may appear susceptible in vitro but are resistant in vivo. About 20% of strains have a nonfunctional erm41 and are truly macrolide susceptible.
This is why macrolide resistance testing must use prolonged incubation (3-5 days), not standard testing.
(Harrison's 22E)

Treatment

General Principles

  • Always seek infectious disease consultation
  • Treatment is prolonged, complex, and multi-drug
  • Susceptibility testing must guide therapy
  • Overall culture conversion rates are low (~35%) for pulmonary disease

Skin, Soft Tissue, and Bone Infections

  • Minimum 4 months (skin/soft tissue); ≥6 months for bone
  • Regimen: Macrolide (clarithromycin or azithromycin) + parenteral agent (amikacin, cefoxitin, or imipenem)

Pulmonary Infection

  • Regimen of at least 3 active drugs based on susceptibility testing:
    • Amikacin + imipenem/cefoxitin + macrolide (if susceptible) ± linezolid ± tigecycline
  • Recent meta-analysis (PMID: 41420504): overall therapeutic efficiency ~35%; amikacin, imipenem, linezolid, and/or tigecycline incorporation → improved outcomes; macrolide resistance → worse outcomes
  • Surgical resection should be considered in patients with good lung reserve and localized infection

Treatment of RGM (Fortuitum / Chelonae) by Red Book

In vitro susceptibility testing should include: amikacin, imipenem, sulfamethoxazole/TMP, cefoxitin, ciprofloxacin, clarithromycin, linezolid, clofazimine, doxycycline, and tigecycline. Removal of prosthetic devices is often required for successful treatment.
(Harrison's 22E; Medical Microbiology 9e; Red Book 2021)

Recent Evidence (2025)

Three recent systematic reviews are relevant:
  1. Treatment outcomes in M. abscessus pulmonary disease (PMID: 41420504, 2025, Ann Acad Med Singapore) - confirms ~35% culture conversion; amikacin/imipenem/linezolid/tigecycline associated with improved outcomes.
  2. Tetracyclines for NTM (focus on RGM) (PMID: 41193247, 2025, Eur Respir Rev) - reviews role of doxycycline/tigecycline in rapidly growing NTM.
  3. NTM after cosmetic procedures (PMID: 39395754, 2024, Int J Infect Dis) - systematic review of RGM infections (predominantly M. abscessus) following cosmetic surgeries, injections, and tattoos.

Key Comparison: M. abscessus vs Other Common NTM

FeatureM. abscessusMAC (M. avium)M. kansasii
GrowthRapid (Runyon IV)Slow (Runyon III)Slow (Runyon I)
Main diseaseLung, skin/soft tissueLung, disseminated (HIV)Lung
First-lineAmikacin + imipenem ± macrolideClarithromycin + ethambutol + rifampinRifampin + ethambutol + isoniazid
Macrolide resistanceCommon (erm41)Acquired (point mutation)Usually susceptible
Treatment success~35% (pulmonary)~60%>80%
Surgical roleImportantSometimesRare

Prevention / Infection Control

  • Standard precautions for hospitalized patients
  • Avoid tap water contamination of central lines, dental equipment, and surgical wounds
  • Use filtered (not tap) water for heater-cooler devices in cardiac surgery
  • Decontamination protocols for dental unit water lines
  • Report suspected heater-cooler device-associated infections to FDA MedWatch
(Red Book 2021)
This is a shared conversation. Sign in to Orris to start your own chat.